

**BIOGRAPHICAL SKETCH**

NAME Robin Ann Lacour, M.D., M.P.H.	POSITION TITLE <b>Staff Physician</b> , Gynecologic Oncologist Willis- Knighton Medical Center, Shreveport, Louisiana <b>Clinical Assistant Professor</b> , Gynecologic Oncology
eRA COMMONS USER NAME (credential, e.g., agency login)	

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)	DEGREE	MM/YY	FIELD OF STUDY
Centre College, Danville, Kentucky	BS	08/1994 – 05/1998	Biology
LSU Health Sciences Center School of Medicine, Shreveport, Louisiana	M.D.	08/1998 – 06/2002	Medicine
Resident, Obstetrics and Gynecology, The University of Texas Southwestern Medical Center, Parkland Hospital, Dallas, Texas		07/2002 – 06/2006	OB/Gyn
Felix Rutledge Fellowship, Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas		March 2005	Fellowship
Fellow, Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, July 2006 – 2010		07/2006 – 06/2010	Fellowship, Gynecologic Oncology
University of Texas School of Public Health, Houston, Texas	MPH	08/2006 – 05/2008	Epidemiology

**A. Personal Statement**

After completing fellowship training in Gynecologic Oncology, I made the decision to return back to Northwest Louisiana to practice. Having graduated from medical school at LSU Health in Shreveport, I was interested in becoming faculty at this institution not only to teach, but to be able to provide Gynecologic Cancer care to patients in the surrounding underserved rural communities. As a Gynecologic Oncologist, I am particularly interested in the apparent disparities associated with survival in patients who present with advanced- stage cervical cancer. In addition, our rural underserved patient population is plagued with obesity, affecting both incidence and survival related to endometrial cancer. In the past 3 years since I have been on faculty at Feist-Weiller Cancer Center, I have had personal experience with difficulty enrolling patients into clinical trials, largely due to social barriers. Participation in the Gulf South- Minority Based NCI Community Oncology Research Program would give me the opportunity to identify and address the specific barriers to clinical trial enrollment for these patients and to promote care cancer delivery, while helping to expand the Health Disparities Research program at Feist- Weiller Cancer Center in Shreveport.

**B. Positions and Honors**

**Primary Appointment**

Staff Physician, Gynecologic Oncologist  
 Willis- Knighton Medical Center, Shreveport, Louisiana

**Dual/Joint/Adjunct Appointments**

Clinical Assistant Professor, Gynecologic Oncology  
Department of Obstetrics and Gynecology  
Louisiana State University Health Sciences Center, Shreveport, Louisiana

**Chair, 2013 Cancer Committee**

Louisiana State University Health Sciences Center, Shreveport, Louisiana

**Selected Honors and Awards**

E. Wilbur Cook Biological Sciences Award, May 1998

John C. Young Research Scholar, 1997-1998

Bernstein Scholarship Recipient, 1999-2000

LSU Honors Scholarship Recipient, 2000-2001

W.R. Matthews Award (Achievement in Pathology Course), 2000

Medical Microbiology Achievement Award, 2000

Alpha Omega Alpha, Vice President, 2001-2002

Academic Excellence Award for Most Improved CREOG Score, 2005

James Robert's Scholarship from Western Association of Gynecologic Oncologists, June 2005

The Linda K. Manning Fellowship in Ovarian Cancer, May 2008

Poster Finalist, The University of Texas M.D. Anderson Cancer Center Trainee Research Day, May 2008

Felix Rutledge Society Award for Best Paper by a Fellow at the Annual Meeting of the Western Association of Gynecologic Oncologists, June 2008

**Selected Peer-reviewed Publications**

1. **Lacour R**, Coleman RL. Virologic versus cytologic triage of women with equivocal pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. *Women's Oncology Review*; 4:107-108, 2004.
2. **Lacour RA**, Garner EI, Molpus KL, Ashfaq R, Schorge JO. Management of cervical adenocarcinoma in situ during pregnancy. *Am J Obstet Gynecol*; 192:1449-1451, 2005.
3. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horowitz IB, **Lacour RA**, Westin SN, Gershenson DM, Wu X, Lu KH. STK15 F31I polymorphism is associated with increased uterine cancer risk: A pilot study. *Gynecol Oncol*; 107:71-74, 2007.
4. **Lacour RA**, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. *Gynecol Oncol*; 111: 132-136, 2008.

5. Westin SN, **Lacour RA**, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: a newly described association with Lynch Syndrome. *J Clin Oncol*; 26: 5965-5971, 2008.
6. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, **Lacour RA**, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen- induced proliferation in obese rat endometrium. *Am J Obstet Gynecol*; 200(2): 186.e1-8, 2009.
7. Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, **Lacour RA**, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS. Molecular clustering of endometrial carcinoma based on estrogen- induced gene expression. *Cancer Biol Ther*; 8(22): 2126-35, 2009.
8. Meyer LA, Anderson ME, **Lacour RA**, Suri A, Daniels MS, Urbauer DL, Noguerras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. *Obstet Gynecol*; 115(5):945-52, 2010.
9. Clements A, Euscher E, **Lacour R**, Merritt W, Klopp A, Ramondetta L. The presence of Human Papillomavirus or p16 in six cases of retroperitoneal carcinoma. *Obstet Gynecol*; 116(5):1042-6, 2010.
10. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, **Lacour RA**, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. *Cancer*; 2010
11. **Lacour RA**, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. *Gynecol Oncol*; 2011
12. **Lacour RA**, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LR. Phase II Trial of Paclitaxel and Carboplatin in Women with Advanced or Recurrent Uterine Carcinosarcoma. *Int J Gynecol Cancer*; 21(3):517-22, 2011.

### Book Chapters

Euscher ED, **Lacour RA**, Ramondetta LM. Predictors of outcome in malignant mixed müllerian tumors of the uterus. In: Levenback C, Coleman R, Lu K, Sood A (eds): *Prognostic and Predictive Factors in Gynecologic Cancers*, Informa UK Ltd, London, 2007.